| Document |
Document Title |
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/116902A1 |
Disclosed are an SOS1 inhibitor represented by formula (X), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof. Further disclosed are a preparation method for ...
|
|
WO/2023/122000A1 |
The disclosure includes compounds of Formulae (1) wherein Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, Qx, R1, R2, R3, R4, R5, R6, R7, R9, R10, R11, Rx, a, b, c, g, j, k, m, n, u, v, L, Z1, Z2, Z4, and Z5 are defined herein. Also disclosed is a metho...
|
|
WO/2023/119210A1 |
The present invention relates to a compound as an RIPK1 inhibitor, a stereoisomer thereof, a tautomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprisi...
|
|
WO/2023/116779A1 |
The present invention relates to a dialkyne compound and the use thereof. Provided is a dialkyne compound as shown in formula I or a pharmaceutically acceptable salt thereof. The dialkyne compound or the pharmaceutically acceptable salt ...
|
|
WO/2023/115165A1 |
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/110936A1 |
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as ...
|
|
WO/2023/111726A1 |
1H-Imidazo[4,5-c]quinolin-4-amine compounds having a triazole ring substituent at the 1-5 position, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods of making the compoun...
|
|
WO/2023/109968A2 |
The invention provides a new synthesis method for a finerenone intermediate. The method comprises: (1) in the presence of an acid and in an inert solvent or under solvent-free conditions, reacting diethyl malonate, 4-cyano-2-methoxybenza...
|
|
WO/2023/114119A1 |
Provided herein are methods of preparing crystalline, selpercatinib Form A, which contains little to none of the thermodynamically more stable, crystalline selpercatinib Form B. Selpercatinib is useful in the treatment and prevention of ...
|
|
WO/2023/110958A1 |
The invention provides new MAGL inhibitors having the general formula (II)AB(II)wherein the variables are as described herein, compositions including the compounds,processes of manufacturing the compounds and methods of using the compounds.
|
|
WO/2023/114809A1 |
Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.
|
|
WO/2023/109926A1 |
Provided are a compound as shown in general formula (I), or a tautomer, mesomer, racemate, enantiomer, or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a protease inhibi...
|
|
WO/2023/114954A1 |
Provided herein are compounds and pharmaceutical compositions thereof for modulating SHP2 and their use in the treatment of disease.
|
|
WO/2023/109883A1 |
Disclosed are a class of compounds having a new structure as an ATR inhibitor, and a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug and a solvate thereof. An in-vitro enzyme inhibitory activity study shows that the com...
|
|
WO/2023/113575A1 |
The present specification relates to a compound of Formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/110742A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/109802A1 |
Disclosed are a tricyclic fused heterocyclic compound having a PDE3/4 dual inhibitory effect represented by formula (I), a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of ...
|
|
WO/2023/110970A1 |
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of BTK (Bruton's Tyrosine Kinase). Moreover, the present invention provides proces...
|
|
WO/2023/112056A1 |
The present invention provides a compound formula (I), Formula (I) wherein, R1, R2, R3, R5, R6, R7, R8, R9, X, Z1 and Z2 are as defined in the detailed description and a process for preparing the compound of formula (I). The present inve...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/114238A1 |
Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorder...
|
|
WO/2023/109761A1 |
The present invention relates to a crystal form of a compound as represented in formula I, various salt types and crystal forms thereof, and further relates to a preparation method for the crystal form of the compound as represented in f...
|
|
WO/2023/111543A1 |
The invention provides compounds of formula: Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds ar...
|
|
WO/2023/109776A1 |
The present invention relates to an FGFR4 inhibitor acid salt, a preparation method therefor, and a use thereof. The FGFR4 inhibitor is a compound N-((3S,4S)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-met
hoxy-3-methylacridine-1-yl)py...
|
|
WO/2023/114456A1 |
Provided herein are compounds and compositions thereof for modulating hepatocyte growth factors. In some embodiments, the compounds and compositions are provided for treatment of diseases, including neurological disorders.
|
|
WO/2023/114844A1 |
Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and/or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorder...
|
|
WO/2023/113478A1 |
The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in the claims for use in the treatment of a neoplastic disease in a subject, wherein said treatment comprises administering the com...
|
|
WO/2023/110664A1 |
Compounds of Formula (I) wherein the substituents are as defined in claim 1. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling wee...
|
|
WO/2023/109254A1 |
Provided in the present invention is a method for one-step direct preparation of 3-acyl imidazo[1,5-a]pyridine by means of [4+1] dual amination reactions of a ketomethyl. The method comprises the following step: electrolyzing 1 equivalen...
|
|
WO/2023/109929A1 |
Provided are a class of compounds, a stereoisomer, an optical isomer, a pharmaceutically acceptable salt, a prodrug, a solvate (for example, a hydrate) or an isotope derivative thereof. The compounds have a tri-heterocyclic structure (fo...
|
|
WO/2023/109521A1 |
A compound of formula (I), a pharmaceutical composition comprising same, and the use thereof as a PARP inhibitor, preferably as a PARP1 selective inhibitor.
|
|
WO/2023/113576A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/109959A1 |
The present invention relates to the field of medicines, specifically relates to a CDK9 inhibitor compound represented by formula (I), and a pharmaceutically acceptable salt or isomer thereof, and also relates to a pharmaceutical composi...
|
|
WO/2023/109775A1 |
Disclosed relates to novel Pyrimidine annulated derivatives of Formula (I) and the preparation methods of these compounds,and to their use as P2Y12 receptor antagonists in the treatment and /or prevention of thrombosis or related disorders.
|
|
WO/2023/109909A1 |
Aromatic heterocyclic compounds as ENPP1 inhibitors, a preparation method therefor and the uses thereof. The compounds have structures as shown in formula (I).
|
|
WO/2023/113577A1 |
The present specification relates to compounds of chemical formula 1 and chemical formula 2 and an organic light-emitting device comprising same.
|
|
WO/2023/109471A1 |
Provided are a compound as represented in general formula (I), and a cis-trans isomer, an enantiomer, a diastereoisomer, a racemate, a solvate, a hydrate or a pharmaceutically acceptable salt or a precursor drug thereof, and a preparatio...
|
|
WO/2023/114428A1 |
The disclosure provides heterocycle derivatives of Formula (I) for the inhibition of the oligosaccharyltransferase complex and the treatment of disease.
|
|
WO/2023/108108A1 |
Described herein are compounds I that are RAF inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/107979A1 |
Provided herein are compositions and methods for the treatment of a cancer. Said compositions comprise an FGFR kinase inhibitor. Some embodiments comprise combination therapy featuring the FGFR kinase inhibitor with at least one oncology...
|
|
WO/2023/104051A1 |
Disclosed is the combined use of an indole substituted tetrahydroisoquinoline compound and a statin compound. Specifically, a safe and non-interaction pharmaceutical composition or pharmaceutical combination. The composition contains an ...
|
|
WO/2023/104209A1 |
Provided are a class of METTL3 inhibitor compounds and a use thereof in preparation of a medication for inhibiting METTL3, thereby providing a new option for clinically selecting and/or preparing a medication for a disease related to MET...
|
|
WO/2023/104170A1 |
One embodiment of the disclosure is a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. The variables in Formula (I) are defined herein. Compounds of Formula (I) can be used to treat polyQ-related neurode...
|
|
WO/2023/107722A1 |
This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating ...
|
|
WO/2023/106973A1 |
The invention relates to a group of compounds which can be used as hepatoprotective agents. The invention further relates to a pharmaceutical composition which exhibits hepatoprotective activity and contains an effective amount of a comp...
|
|
WO/2023/104111A1 |
The present disclosure describes antagonists of the enzyme. The present disclosure provides compounds having a structure set forth in Formula (VI), (VII), (VII-1) or (VIII), the stereoisomer or pharmaceutically acceptable salts, solvates...
|
|
WO/2023/103898A1 |
Provided is a novel compound having a macrocyclic structure. Specifically, provided are a compound having a macrocyclic structure of formula (I), or a pharmaceutically acceptable salt or a deuterated form thereof, and a method for prepar...
|
|
WO/2023/107597A2 |
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurolo...
|
|
WO/2023/107705A1 |
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
